[HTML][HTML] Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002-2004
TJ Cicero, JA Inciardi, A Muñoz - The Journal of Pain, 2005 - Elsevier
OxyContin®(Purdue Pharma LP, Stamford, Conn) was approved by the Food and Drug
Administration (FDA) in 1995 as a sustained-release preparation of oxycodone
hydrochloride and was thought to have much lower abuse potential than immediate-release
oxycodone because of its slow-release properties. However, beginning in 2000, widespread
reports of OxyContin® abuse surfaced. In response, Purdue Pharma LP sponsored the
development of a proactive abuse surveillance program, named the Researched Abuse …
Administration (FDA) in 1995 as a sustained-release preparation of oxycodone
hydrochloride and was thought to have much lower abuse potential than immediate-release
oxycodone because of its slow-release properties. However, beginning in 2000, widespread
reports of OxyContin® abuse surfaced. In response, Purdue Pharma LP sponsored the
development of a proactive abuse surveillance program, named the Researched Abuse …
以上显示的是最相近的搜索结果。 查看全部搜索结果